Pink Sheet, August 2, 2023: This news article extensively describes 2 letters sent to CMS about the Leqembi registries: one from policy experts and one from 20 members of the Patient, Consumer, & Public Health Coalition. The article explains what these experts are asking Medicare to require of private registries for patients with mild cognitive impairment caused by early Alzheimer’s.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly
STAT, July 27, 2023: Prestigious health policy experts and ethicists sent a letter to CMS to urge Medicare to require all Alzheimer’s drug registries to share their de-identified data publicly to allow statistical analyses by CMS and others. NCHR explains why that is important, but Alzheimer’s Association and Beth Israel Hospital don’t plan to comply.
Read More »US Mammogram Update Sparks Concern, Reignites Debates
Medscape, July 9, 2023:Medscape quotes experts disagreeing about what age (40? 50? to start mammograms and we point out that the science suggests different guidelines based on race and risk. Radiologists suggest Black women start at age 35, which would means $$$ for the radiologists but would do more harm than good for most women. USPSTF recommendations raise concerns about costs, accuracy, timing, and ensuring that abnormal mammograms result in biopsies to learn if treatment is needed.
Read More »Alzheimer’s Drug Safety Hinges on Doctors Heeding FDA Warning
Bloomberg Law News, July 12, 2023: NCHR says the FDA black box warnings about brain swelling and bleeding and other cautions about who is most likely to be harmed by Alzheimer’s drug Leqembi will help protect patients with mild cognitive impairment, but only if their doctors pay attention and accurately discuss the risks vs. uncertain benefits with patients and family members.
Read More »No more FDA adcomm votes? Reforms brew as new research highlights decline in meetings
Endpoints News, July 7, 2023: FDA wants to revamp its Advisory Committee meetings but will they make them better or worse? The votes aren’t the problem. We explain that the conflicts of interest of committee members is “outrageous.”
Read More »